• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Loss of heterozygosity on 10q23 is involved in metastatic recurrence of hepatocellular carcinoma.10q23杂合性缺失与肝细胞癌的转移复发有关。
Cancer Sci. 2009 Mar;100(3):520-8. doi: 10.1111/j.1349-7006.2008.01056.x. Epub 2008 Dec 11.
2
Relationship between loss of heterozygosity at microsatellite loci and computerized nuclear morphometry in hepatocellular carcinoma.肝细胞癌中微卫星位点杂合性缺失与计算机化核形态测量学之间的关系。
Anticancer Res. 2000 Mar-Apr;20(2B):1257-62.
3
Loss of heterozygosity on chromosome 10q23 and mutation of the phosphatase and tensin homolog deleted from chromosome 10 tumor suppressor gene in Korean hepatocellular carcinoma patients.韩国肝细胞癌患者10号染色体长臂23区杂合性缺失及10号染色体缺失的磷酸酶及张力蛋白同源物肿瘤抑制基因突变
Oncol Rep. 2007 Oct;18(4):1007-13.
4
Loss of heterozygosity at D8S298 is a predictor for long-term survival of patients with tumor-node-metastasis stage I of hepatocellular carcinoma.D8S298位点杂合性缺失是肝细胞癌肿瘤-淋巴结-转移I期患者长期生存的一个预测指标。
Clin Cancer Res. 2007 Dec 15;13(24):7363-9. doi: 10.1158/1078-0432.CCR-07-0593.
5
Genome-wide analyses on loss of heterozygosity in hepatocellular carcinoma in Southern China.中国南方肝细胞癌杂合性缺失的全基因组分析。
J Hepatol. 2001 Jun;34(6):840-9. doi: 10.1016/s0168-8278(01)00047-2.
6
Prognostic impact of multiple allelic losses on metastatic recurrence in hepatocellular carcinoma after curative resection.根治性切除术后多等位基因缺失对肝细胞癌转移复发的预后影响
Oncology. 2002;62(2):141-8. doi: 10.1159/000048260.
7
The association of frequent allelic loss on 17p13.1 with early metastatic recurrence of hepatocellular carcinoma after liver transplantation.17p13.1 上频繁的等位基因缺失与肝移植后肝细胞癌的早期转移复发相关。
J Surg Oncol. 2010 Dec 1;102(7):802-8. doi: 10.1002/jso.21743.
8
[Genome-wide loss of heterozygosity analyses in primary hepatocellular carcinoma].[原发性肝细胞癌全基因组杂合性缺失分析]
Zhonghua Yi Xue Za Zhi. 2000 Aug;80(8):577-81.
9
Loss of heterozygosity on chromosome 10q22-10q23 and 22q11.2-22q12.1 and p53 gene in primary hepatocellular carcinoma.原发性肝细胞癌中10q22 - 10q23、22q11.2 - 22q12.1染色体杂合性缺失及p53基因情况
World J Gastroenterol. 2004 Jul 1;10(13):1975-8. doi: 10.3748/wjg.v10.i13.1975.
10
A critical role for ZDHHC2 in metastasis and recurrence in human hepatocellular carcinoma.ZDHHC2在人类肝细胞癌转移和复发中的关键作用。
Biomed Res Int. 2014;2014:832712. doi: 10.1155/2014/832712. Epub 2014 Jun 9.

引用本文的文献

1
Genetic alterations in hepatocellular carcinoma: An update.肝细胞癌中的基因改变:最新进展
World J Gastroenterol. 2016 Nov 7;22(41):9069-9095. doi: 10.3748/wjg.v22.i41.9069.
2
A critical role for ZDHHC2 in metastasis and recurrence in human hepatocellular carcinoma.ZDHHC2在人类肝细胞癌转移和复发中的关键作用。
Biomed Res Int. 2014;2014:832712. doi: 10.1155/2014/832712. Epub 2014 Jun 9.
3
LOH analysis of genes around D4S2964 identifies ARD1B as a prognostic predictor of hepatocellular carcinoma.分析 D4S2964 附近基因的 LOH,发现 ARD1B 是肝细胞癌的预后预测因子。
World J Gastroenterol. 2010 Apr 28;16(16):2046-54. doi: 10.3748/wjg.v16.i16.2046.

本文引用的文献

1
Novel advancements in the management of hepatocellular carcinoma in 2008.2008年肝细胞癌管理方面的新进展。
J Hepatol. 2008;48 Suppl 1:S20-37. doi: 10.1016/j.jhep.2008.01.022. Epub 2008 Feb 12.
2
Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation.扩大活体肝移植中肝细胞癌患者的选择标准。
Liver Transpl. 2007 Dec;13(12):1637-44. doi: 10.1002/lt.21281.
3
Liver transplantation for solitary hepatocellular carcinoma less than 3 cm in diameter in Child A cirrhosis.针对Child A级肝硬化中直径小于3厘米的孤立性肝细胞癌进行肝移植。
Dig Dis. 2007;25(4):334-40. doi: 10.1159/000106914.
4
Loss of heterozygosity on chromosome 10q23 and mutation of the phosphatase and tensin homolog deleted from chromosome 10 tumor suppressor gene in Korean hepatocellular carcinoma patients.韩国肝细胞癌患者10号染色体长臂23区杂合性缺失及10号染色体缺失的磷酸酶及张力蛋白同源物肿瘤抑制基因突变
Oncol Rep. 2007 Oct;18(4):1007-13.
5
Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan.肝细胞癌的分期:对日本13772例患者队列中日本TNM和AJCC/UICC TNM系统的评估
Ann Surg. 2007 Jun;245(6):909-22. doi: 10.1097/01.sla.0000254368.65878.da.
6
Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro.雷帕霉素通过在体外诱导肝癌细胞凋亡来抑制细胞生长。
Transpl Immunol. 2007 Apr;17(3):162-8. doi: 10.1016/j.trim.2006.12.003. Epub 2007 Jan 16.
7
Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma.活体肝移植作为肝细胞癌患者的二线治疗策略。
Liver Transpl. 2006 Jun;12(6):912-9. doi: 10.1002/lt.20642.
8
Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma.肿瘤大小可预测血管侵犯和组织学分级:对肝细胞癌手术治疗选择的意义。
Liver Transpl. 2005 Sep;11(9):1086-92. doi: 10.1002/lt.20472.
9
Comparison between the fifth and sixth editions of the AJCC/UICC TNM staging systems for hepatocellular carcinoma: multicentric study on 393 cirrhotic resected patients.AJCC/UICC肝细胞癌TNM分期系统第五版与第六版的比较:对393例接受手术切除的肝硬化患者的多中心研究
Eur J Surg Oncol. 2005 Sep;31(7):760-7. doi: 10.1016/j.ejso.2005.04.008.
10
Artificial neural network and tissue genotyping of hepatocellular carcinoma in liver-transplant recipients: prediction of recurrence.肝移植受者肝细胞癌的人工神经网络与组织基因分型:复发预测
Transplantation. 2005 Jun 27;79(12):1737-40. doi: 10.1097/01.tp.0000161794.32007.d1.

10q23杂合性缺失与肝细胞癌的转移复发有关。

Loss of heterozygosity on 10q23 is involved in metastatic recurrence of hepatocellular carcinoma.

作者信息

Okuno Tomoko, Ueda Mikiko, Tsuruyama Tatsuaki, Haga Hironori, Takada Yasutsugu, Maetani Yoji, Tamaki Keiji, Manabe Toshiaki, Tanaka Koichi, Uemoto Shinji

机构信息

Laboratory of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.

出版信息

Cancer Sci. 2009 Mar;100(3):520-8. doi: 10.1111/j.1349-7006.2008.01056.x. Epub 2008 Dec 11.

DOI:10.1111/j.1349-7006.2008.01056.x
PMID:19077004
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11158083/
Abstract

We performed loss of heterozygosity (LOH) analysis on five chromosomal arms (1p, 3p, 9p, 10q, 17p) in hepatocellular carcinoma (HCC). Univariate analyses of 80 patients who underwent liver transplantation demonstrated significant correlations between cancer recurrence and the following variables: LOH on 3p26, LOH on 10q23, LOH on 17p13, tumor diameter > or = 5 cm, number of tumors > or = 4, histologic Grade 3, alpha-fetoprotein (AFP) > or = 400 ng/mL, American Joint Committee on Cancer (AJCC) pT classification, and portal invasion. Patients with LOH on 10q23 exhibited a significantly higher 3-year recurrence rate (38.9%vs 11.9%, P = 0.0009). Multivariate analysis identified LOH on 10q23, histologic Grade 3, tumor nodules > or = 4, and AFP > or = 400 ng/mL as the risk factors of advanced HCC recurrence. These results suggest that LOH on 10q23 is associated with metastatic recurrence of HCC.

摘要

我们对肝细胞癌(HCC)的五条染色体臂(1p、3p、9p、10q、17p)进行了杂合性缺失(LOH)分析。对80例行肝移植的患者进行单因素分析,结果显示癌症复发与以下变量之间存在显著相关性:3p26处的LOH、10q23处的LOH、17p13处的LOH、肿瘤直径≥5 cm、肿瘤数量≥4个、组织学3级、甲胎蛋白(AFP)≥400 ng/mL、美国癌症联合委员会(AJCC)pT分类以及门静脉侵犯。10q23处存在LOH的患者3年复发率显著更高(38.9%对11.9%,P = 0.0009)。多因素分析确定10q23处的LOH、组织学3级、肿瘤结节≥4个以及AFP≥400 ng/mL为晚期HCC复发的危险因素。这些结果表明,10q23处的LOH与HCC的转移复发相关。